New Jersey providers face a continuous stream of payer policy changes: coverage edits, prior authorization expansions, billing code revisions, and Medicaid reimbursement updates that affect day-to-day practice operations. This page surfaces every tracked policy change that explicitly names New Jersey, so your billing and compliance teams can act before the effective date, not after a claim denial.
UnitedHealthcare Community Plan of New Jersey has narrowed TMJ surgical coverage to only arthroplasty (removing arthroscopy, discectomy, and reconstruction from covered services) and updated clinical coverage criteria references for Medicaid beneficiaries in New Jersey. Four CPT codes (21060, 21247, 29800, 29804) have been removed from applicable codes, effective December 1, 2026.
UnitedHealthcare Community Plan of New Jersey (Medicaid) revised its coverage policy for cardiovascular disease risk tests, effective December 1, 2026. The policy narrowed the exclusion for advanced lipoprotein analysis (now excluding only subfractions/particle size, not lipoprotein(a)), added exclusion for noninvasive point-of-care cardiac diagnostic platforms using machine learning (e.g., CorVista System), updated applicable CPT codes, and removed CPT 83695 from the billable codes list.
Effective December 5, 2026, Evolent will implement site-of-care selection requirements for shoulder, hip, knee, and spine surgeries for Ambetter from WellCare of New Jersey members. Ordering providers must now specify preferred outpatient or inpatient settings during authorization requests; hospital-based settings for outpatient-eligible procedures require either selection from allowable exceptions or clinical justification. Clinical reviewers will evaluate both medical necessity and site of care before authorization is finalized.
Effective January 1, 2027, UnitedHealthcare is adding prior authorization requirements for 11 HCPCS oncology medication codes when administered in outpatient settings for cancer treatment. These codes include busulfan, leucovorin calcium, luspatercept, dexrazoxane, dinutuximab, octreotide, triptorelin, omidubicel, zoledronic acid, and cyclosporine. This change applies across commercial, Medicare Advantage, Medicaid, and Individual Exchange plans.
New Jersey Medicaid/NJ FamilyCare mandates that Personal Care Assistance (PCA) and Home Health Services (HHS) providers must achieve 80% Electronic Visit Verification (EVV) compliance by January 1, 2027, with no more than 20% manual edits allowed. Providers failing to meet this threshold face progressive sanctions including loss of new referrals, contract termination, and one-year ineligibility. The policy includes a three-month compliance period (October 1 – December 31, 2026) and defines six required EVV data elements with specific edit reason codes.
Effective January 1, 2027, Ambetter from WellCare of New Jersey will discontinue coverage for 45 HCPCS H codes (behavioral health and substance abuse treatment services) while adding coverage for H0006. Billing teams must identify all claims using the discontinued codes and implement alternative billing strategies or prior authorization processes before the effective date.
UnitedHealthcare Community Plan of New Jersey's November 2026 Medicaid medical policy bulletin adds a new policy, effective 2026-12-01, on vascular embolization for select procedures. Renal embolization is covered as medically necessary for preoperative or palliative treatment of renal cell carcinoma and for nonruptured angiomyolipomas at elevated bleeding risk, while transarterial bland embolization or chemoembolization for liver malignancies follows InterQual criteria and other oncologic indications follow NCCN guidelines. Arterial embolization for hemorrhoids and for musculoskeletal pain (knee and shoulder osteoarthritis, adhesive capsulitis, tendinitis, plantar fasciitis) is labeled unproven and not medically necessary, and the policy excludes members under 18 and acute or active bleeding indications.
Effective December 1, 2026, UnitedHealthcare Community Plans in Kansas, Kentucky, and New Jersey will implement a new vascular embolization policy and add prior authorization requirements for CPT code 37242. Services previously evaluated under multiple existing policies will now be consolidated under unified clinical criteria for therapeutic vascular embolization procedures.
UnitedHealthcare Community Plan of New Jersey (Medicaid) revised coverage criteria for Transarterial Radioembolization (TARE)/Selective Internal Radiation Therapy (SIRT) using yttrium-90 microspheres effective December 1, 2026. The policy now specifies five covered indications for liver cancer treatment (including a change from 'uveal/ocular melanoma metastasis' to 'uveal melanoma metastasis'), applies only to patients age 19+ with ECOG Performance Status 0-2, and automatically covers patients under 19 without prior authorization.
UnitedHealthcare Community Plan of New Jersey (Medicaid) revised its breast imaging policy effective December 1, 2026, clarifying coverage criteria for breast MRI in high-risk individuals and refining the list of unproven/non-covered modalities. Key changes include refined definitions of Molecular Breast Imaging and removal of Breast Specific Gamma Imaging as a separate definition. Breast MRI is now clearly covered for specific high-risk populations including those with dense breasts, genetic mutations, personal/family history of breast cancer, and prior chest radiation—but remains non-covered for individuals who do not meet these criteria.
UnitedHealthcare Community Plan of New Jersey revised its Saphnelo (anifrolumab-fnia) IV medical policy, effective 2027-01-01. A new continuation and initial criterion requires the prescriber to attest that the patient or caregiver cannot be trained or is physically unable to self-administer Saphnelo or Benlysta, with an explanation submitted, and initial and continuation authorizations are limited to no more than 12 months. Saphnelo for severe active lupus nephritis, severe active CNS lupus, or use with other biologics is listed as not medically necessary.
UnitedHealthcare Community Plan of New Jersey revised its FcRn Blockers medical benefit drug policy, expanding coverage for Imaavy (nipocalimab-aahu) in warm autoimmune hemolytic anemia (wAIHA) in adults and pediatric patients 12 and older who are currently or previously treated with corticosteroids. Billing teams should expect new medical-record documentation requirements (confirmed diagnosis, DAT results, prescriber involvement, and prior treatment history), a 12-month initial authorization limit, and the addition of ICD-10 code D59.11 to applicable diagnosis codes.
UnitedHealthcare Community Plan of New Jersey revised its Whole Exome and Whole Genome Sequencing (Non-Oncology Conditions) medical policy for New Jersey Medicaid, effective 2027-01-01. Revisions include broadening who may order the test to 'by or in consultation with' a medical geneticist, neonatologist, neurologist, immunologist, or developmental pediatrician, adding criteria for exome and genome data reanalysis after at least 18 months, restricting the policy to outpatient testing or testing upon discharge from an inpatient setting, and adding CPT codes 0670U through 0677U. The policy also notes that CPT codes 0657U, 0658U, 0659U, 0670U-0677U, and 81354 are not on the New Jersey Medicaid fee schedule and may not be covered by the New Jersey Medicaid program.
UnitedHealthcare Community Plan of New Jersey's November 2026 medical policy bulletin updates the Occipital Nerve Injections and Ablation policy for New Jersey Medicaid members: CPT codes 1057T, 1058T, 1059T, 1060T and 1061T are added, and CPT 64570 is removed. The bulletin notes that the newly added codes are not on the State of New Jersey Medicaid Fee Schedule and therefore may not be covered by the New Jersey Medicaid Program. The billing team should verify coverage status before scheduling or billing these services for affected members.
UnitedHealthcare Community Plan of New Jersey revised its Medicaid medical policy for molecular oncology testing in hematologic cancers, effective 2027-01-01. Multigene panel testing of up to 50 genes is covered when ordered by a hematologist or oncologist at initial diagnosis or relapse for listed conditions (adding mantle cell lymphoma), clonoSEQ clonality and MRD testing is covered for listed conditions, and CPT codes 0332U, 0592U, 0644U and 0645U were added while 0485U, 0560U and 0561U were removed; all other molecular oncology testing is stated as unproven and not medically necessary, including EpiSwitch Checkpoint Inhibitor Response Test, optical genome mapping and whole-transcriptome sequencing.
UnitedHealthcare Community Plan of New Jersey updated its Bariatric Surgery medical policy in its November 2026 bulletin, effective 2027-01-01. The update removes CPT code 43882 from the applicable codes list and removes the Medical Records Documentation Used for Reviews section, with documentation guidance now referenced on UHCprovider.com under Community Plans > Resources and FAQs.
AmeriHealth will update its list of specialty drugs requiring precertification under medical benefits effective January 1, 2027. This change affects members in AmeriHealth HMO plans, AmeriHealth Insurance Company of New Jersey plans, and AmeriHealth Commercial and Medicare Advantage PPO plans administered by AmeriHealth Administrators. Billing teams must verify the updated specialty drug precertification list and adjust prior authorization workflows accordingly.
Horizon Blue is transitioning pharmacy prior authorization submissions to electronic Prior Authorization (ePA) through vendors like CoverMyMeds or SureScripts. Beginning January 1, 2027, New Jersey State Mandate will require ePA for all pharmacy prescription drug prior authorization requests (formulary exceptions, tier exceptions, quantity limit reviews).
Horizon Blue Cross Blue Shield of New Jersey is encouraging providers to submit medication prior authorizations electronically using ePA tools (CoverMyMeds or SureScripts) through Prime Therapeutics, with no cost to practices. This aligns with a New Jersey state mandate requiring electronic PA submission beginning January 1, 2027.
UnitedHealthcare Community Plan of New Jersey added a Medicaid medical benefit drug policy for Pasatru (garetosmab-grts) for fibrodysplasia ossificans progressiva (FOP), effective 2026-12-01. Initial therapy requires an age over 18, an FOP diagnosis, supporting chart notes and ACVR1 genetic testing, prescribing by or in consultation with an FOP expert, FDA-labeled dosing, no combination with Sohonos (palovarotene), and authorization for no more than 12 months; continuation requires documented positive response and renewal for no more than 12 months.
UnitedHealthcare Community Plan of New Jersey published a new Medicaid medical benefit drug policy for Genglycos (pariglasgene brecaparvovec-opnr), a gene therapy for glycogen storage disease type Ia, effective 2026-12-01. Coverage is limited to patients aged 8 or older with a confirmed GSDIa diagnosis (G6PC bi-allelic variants or absent G6Pase activity on liver biopsy), on a current cornstarch regimen, without detectable AAV8 antibodies, no prior gene therapy, prescribed by or with a metabolic specialist, no planned inpatient admission solely for administration, dosed per FDA labeling, and authorized for one lifetime treatment for up to 45 days from approval.
UnitedHealthcare Community Plan of New Jersey updated its spinal fusion and decompression coverage policy effective November 1, 2026. Key changes include: (1) Updated medical necessity criteria to reference the InterQual® Client Defined, CP: Procedures, Decompression +/- Fusion, Lumbar (Custom) - UHG instead of the standard InterQual® criteria; (2) Added new definitions for Anticipated Instability Due to Procedure, Instability, and Lumbar Spinal Decompression; (3) Clarified that staged/serial procedures for multisite spinal pathology in one session are unproven and not medically necessary; and (4) Reaffirmed that dynamic stabilization systems, facet joint replacement, isolated facet joint fusion, and vertebral joint implants are not covered.
Effective October 1, 2026, AmBetter Health will no longer reimburse CPT codes 80320–80377 (Definitive Drug Testing Procedures). Billing teams must stop submitting claims for these codes and instead bill the appropriate G-series bundled laboratory codes to avoid claim denials.
This is a comprehensive Medicare Advantage coverage policy for molecular biomarker tests used in prostate cancer risk stratification (effective 10/1/2026). The policy establishes coverage criteria for tests like ArteraAI, EpiSwitch, IsoPSA, MyProstateScore 2.0, ProMark, and ProsTAV, with coverage determinations based on MAC-specific LCDs/LCAs that vary by geographic jurisdiction. Billing teams must identify the correct MAC jurisdiction and apply the corresponding LCD requirements for each test ordered.
AmeriHealth (HMO and Insurance Company of New Jersey) has updated fee schedules effective October 1, 2026, now available on the PEAR provider portal. The billing team must access and review these updated schedules to ensure accurate reimbursement rates for all AmeriHealth plans going forward.
This is a comprehensive Medicare Advantage bariatric surgery coverage policy (HUM-1020-005) effective October 1, 2026, that outlines coverage determinations, limitations, and coding requirements for various bariatric procedures. The policy applies Humana's Medicare Advantage coverage standards and references applicable MAC Local Coverage Determinations by geographic jurisdiction, with specific rules varying by state and MAC region.
This is a revised Medicare Advantage medical coverage policy for spinal fusion surgery (effective 09/01/2026) that consolidates coverage determination, limitations, coding information, and evidence summaries for cervical, lumbar, and thoracic spinal fusion procedures. The policy references multiple MAC-specific Local Coverage Determinations (LCDs) across geographic jurisdictions and outlines covered procedures including traditional fusion, minimally invasive approaches (DLIF, XLIF, MITLIF), sacroiliac joint fusion, and interlaminar fusion techniques. Billing teams must align claims submission with the applicable MAC LCD based on patient location and ensure procedures meet specific medical necessity criteria outlined in the referenced determinations.
This is a comprehensive Medicare Advantage coverage policy for Benign Prostatic Hyperplasia treatments effective September 1, 2026. The policy outlines coverage determinations for multiple BPH treatment modalities including surgical procedures (TURP, prostatectomy, laser therapies), temporary implanted devices, stents, and diagnostic testing. The policy references multiple MAC-specific Local Coverage Determinations (LCDs) that vary by geographic jurisdiction, requiring billing teams to verify applicable coverage rules based on patient location.
Humana Medicare Advantage has revised its Ambulatory Cardiac Monitoring Devices policy effective September 1, 2026. The policy provides updated coverage guidance for various cardiac monitoring technologies (Holter monitors, patch recorders, external loop monitors, implantable loop recorders, and mobile cardiac outpatient telemetry) with MAC-specific coverage determinations by geographic jurisdiction. The policy document appears incomplete but establishes that medical necessity determinations will follow applicable NCDs and LCDs based on the member's jurisdiction.
Ambetter from WellCare of New Jersey is implementing new billing and payment criteria for Intraoperative Neurophysiologic Monitoring (IONM) services effective September 1, 2026. Only CMS-recognized payable code 95940 with modifier G0453 will be covered; code 95941 is non-covered. Billing must comply with strict criteria including exclusive patient attention, maximum 4 units per 60 minutes, and appropriate place of service codes (19, 21, 22, or 24). IONM cannot be billed by surgeons or anesthesia providers as it is included in the global surgical package.
Effective September 1, 2026, Synapse Health will manage DME ordering and fulfillment for select UnitedHealthcare Medicare Advantage plans in multiple states. Providers must transition to prescribing through the Synapse Health e-prescribing portal, and DME suppliers must join the Synapse Health network to continue serving UnitedHealthcare members. This change affects Individual HMO/PPO plans, C-SNP, and D-SNP plans in 11 states, with a defined list of covered and non-covered DME categories.
This is a comprehensive Medicare Advantage coverage policy for neuroablative techniques used to treat chronic pain, effective 08/06/2026. The policy defines coverage criteria, eligible procedures (including radiofrequency ablation, cryoablation, chemical neurolysis, and specialized devices like Intracept), and references MAC-specific LCDs and billing codes by geographic jurisdiction. Billing teams must verify applicable MAC guidelines for their state and ensure claims comply with local coverage determinations.
This is a comprehensive Medicare Advantage policy on neuroablative techniques for chronic pain management, effective 08/06/2026. The policy defines covered denervation procedures (radiofrequency ablation, cryoablation, facet denervation, basivertebral nerve ablation, and others) and references MAC-specific LCDs and NCDs that vary by geographic jurisdiction. Billing teams must verify applicable MAC requirements for their region before processing claims for these procedures.
This is a comprehensive Medicare Advantage policy on genetic testing for hereditary cancer syndromes, effective August 3, 2026. The policy establishes coverage guidelines for germline genetic testing across multiple cancer types (melanoma, gastric cancer, neuroendocrine tumors, renal cell carcinoma, and others) and references specific MAC-based Local Coverage Determinations (LCDs) that vary by geographic jurisdiction. Billing teams must verify applicable MAC jurisdiction and LCD requirements before processing claims.
Humana Medicare Advantage has revised its breast reconstruction coverage policy (effective 08/03/2026) to clarify medical necessity criteria for reconstruction procedures following mastectomy, trauma, or congenital abnormalities. The policy applies MAC-specific Local Coverage Determinations (LCDs) by geographic jurisdiction and establishes criteria for determining coverage of implant removal, reduction mammaplasty, and related procedures. Billing teams must identify the appropriate MAC jurisdiction for each claim and apply the correct LCD requirements.
Humana Medicare Advantage has updated its Breast Excision and Mastectomy policy (HUM-1254-009) effective 08/03/2026. This revised policy clarifies coverage criteria for breast lesion excisions (CPT 19120, 19125), partial mastectomies (CPT 19301, 19302), and gynecomastia mastectomy (CPT 19300) across multiple MAC jurisdictions. The policy establishes specific medical necessity criteria based on biopsy results, lesion characteristics, and anatomical considerations, and applies jurisdiction-specific Local Coverage Determinations (LCDs) for Medicare Administrative Contractors.
This is a comprehensive Medicare Advantage policy for Benign Prostatic Hyperplasia (BPH) treatments that became effective on August 3, 2026. The policy outlines coverage for multiple surgical and minimally invasive treatment modalities including TURP, laser therapies, temporary implanted devices, and stents, with specific coverage determinations varying by MAC jurisdiction. Billing teams must verify applicable MAC-specific LCDs and NCDs by geographic location before processing BPH treatment claims.
AmeriHealth has updated their fee schedules effective July 1, 2026, which are now available on the PEAR portal. Billing teams need to access the updated fee schedules to ensure proper reimbursement rates are being used for AmeriHealth HMO and AmeriHealth Insurance Company of New Jersey claims.
Effective June 27, 2026, Horizon Blue Cross Blue Shield will implement a new Prior Authorization requirement for 12 categories of outpatient elective surgical procedures for New Jersey State Health Benefits Program (SHBP) members only. PA reviews will assess medical necessity and/or Site of Service appropriateness for Hospital Outpatient Department (HOPD) procedures, though Ambulatory Surgery Center (ASC) procedures are exempt from SOS review.
Effective June 1, 2026, Horizon Blue Cross Blue Shield will no longer accept claim disputes submitted by phone for Horizon NJ Health (Medicaid) and Federal Employee Program (FEP) members. All claim disputes must be submitted through the Provider Portal (Availity Essentials). Claim appeals remain unchanged and must continue to be submitted in writing.
Effective June 1, 2026, New Jersey Medicaid will implement new claims edits that pend or deny claims submitted for services rendered when a provider's required license is expired, inactive, suspended, or invalid. Billing teams must verify all providers' licensure information is current in the NJMMIS system and submit updated licenses to Gainwell Provider Enrollment if not listed, or claims will be denied after a 4-week pend period.
Independence Blue Cross updated policy 00.01.25bv to reflect CPT/HCPCS code changes effective 04/01/2026 and 07/01/2026. Three prosthetic/orthotic codes (L6000, L6010, L6020) were terminated, four laboratory codes were terminated, two DME codes were added, one CPT code was added, and four laboratory codes had narrative revisions. Billing teams must update systems to reflect these code status changes and removed codes must not be billed effective their termination dates.
Independence Blue Cross updated MA08.126c to expand Uplizna® (inebilizumab-cdon) coverage to include two new FDA-approved indications: immunoglobulin G4-related disease (IgG4-RD) and generalized myasthenia gravis (gMG), in addition to the existing NMOSD indication. All ICD-10 diagnosis codes were removed from the policy; billing teams must now report the most appropriate diagnosis code supporting medical necessity criteria. Effective immediately (03/23/2026).
New Jersey PAAD/Senior Gold pharmacy claims will be denied starting March 15, 2026 if Medicare Part D patient responsibility amounts exceed the $2,100 annual out-of-pocket maximum or LIS copayment limits ($5.10 generic, $12.65 brand). Pharmacies must ensure proper secondary billing to avoid new error codes 2358 and 2359.
Effective March 1, 2026, Highmark will reject or deny all span-dated (range-dated) claims subject to Medically Unlikely Edits (MUEs). Professional providers must submit HCPCS procedure codes with individual dates of service instead of date ranges to comply with National Correct Coding Initiative guidelines and correct coding principles.
New Jersey now requires ABA, DIR, BA, and IIC providers to complete FBI background checks instead of state-only checks. Existing employees have until April 26, 2026 to complete the new federal background check requirement.
UnitedHealthcare Community Plan (Medicaid) now requires enhanced medical documentation for prior authorization of total hip and knee joint replacement surgeries (CPT 27447, 27130, 27132) when performed for osteoarthritis. New requirements include detailed imaging reports with specific findings and provider specialties who interpreted images, rolling out across multiple states with different effective dates.
Effective October 1, 2025, Bausch Health and select AbbVie products are withdrawn from New Jersey's PAAD and Senior Gold prescription assistance programs due to terminated rebate agreements. PAAD and Senior Gold beneficiaries will no longer receive copay assistance for drugs under 47 Bausch Health labeler codes and 3 AbbVie labeler codes; patients will be responsible for full copay costs unless they pursue tier reduction or manufacturer patient assistance programs.
Independence Blue Cross updated policy 00.01.25bt to 00.01.25bv, effective 10/01/2025, adding 39 new CPT/HCPCS codes for DME, laboratory, radiology, and physical medicine services, and revising narratives for 7 existing codes. Billing teams must verify that claims for these newly added codes comply with PPO network rules regarding eligible provider types and settings before submission.
New Jersey Medicaid is increasing reimbursement rates for primary care services to 70% of Medicare rates, effective July 1, 2025. This applies to evaluation and management codes (99202-99499) and immunization administration codes, with managed care organizations required to use these as minimum payment rates.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.